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Background: Major goals in translational oncology are to reduce systemic toxicity of current anticancer strategies
and improve effectiveness. An extremely efficient cancer cell mechanism to avoid and/or reduce the effects of
highly cytotoxic drugs is the establishment of an acidic microenvironment, an hallmark of all malignant tumors. The
H + −rich milieu that anticancer drugs meet once they get inside the tumor leads to their protonation and
neutralization, therefore hindering their access into tumor cells. We have previously shown that proton pump
inhibitors (PPI) may efficiently counterattack this tumor advantage leading to a consistent chemosensitization of
tumors. In this study, we investigated the effects of PPI in chemosensitizing osteosarcoma.
Method: MG-63 and Saos-2 cell lines were used as human osteosarcoma models. Cell proliferation after
pretreatment with PPI and subsequent treatment with cisplatin was evaluated by using erythrosin B dye vital
staining. Tumour growth was evaluated in xenograft treated with cisplatin after PPI pretreatment. Subsequently, a
multi-centre historically controlled trial, was performed to evaluate the activity of a pre-treatment administration of
PPIs as chemosensitizers during neoadjuvant chemotherapy based on methotrexate, cisplatin, and adriamycin.
Results: Preclinical experiments showed that PPI sensitize both human osteosarcoma cell lines and xenografts to
cisplatin. A clinical study subsequently showed that pretreatment with PPI drug esomeprazole leads to an increase
in the local effect of chemotherapy, as expressed by percentage of tumor necrosis. This was particularly evident in
chondroblastic osteosarcoma, an histological subtype that normally shows a poor histological response. Notably, no
significant increase in toxicity was recorded in PPI treated patients.
Conclusion: This study provides the first evidence that PPI may be beneficially added to standard regimens in
combination to conventional chemotherapy.Introduction
Low pH is a major cause of tumor unresponsiveness to
the vast majority of cytotoxic drugs mostly due to the
fact the H + −rich tumor microenvironment leads to
protonation of the drug causing both its neutralization
outside the cells and abrogation of drug entry within the
target cell [1]. The prime cause of tumor microenviron-
ment acidification is the Warburg effect, which leads to
overproduction of lactic acid by malignant tumors. How-
ever, this condition progressively selects cells that live in* Correspondence: stefano.fais@iss.it
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reproduction in any medium, provided the orthe acidic microenvironment due to overexpression and
function of proton pumps that avoid intracellular acidifi-
cation [2]. Vacuolar-type H + −ATPases play a key role in
the acidification of tumor microenvironment [2]. Under
experimental conditions, pretreatment of drug-resistant
tumor cells with proton pump inhibitors (PPI) increases
tumor cells sensitivity to a variety of anticancer drugs
[3]. Pretreatment with PPI, followed by the administration
of anticancer drug, both in vitro and in vivo, resulted in
the most efficient approach. This effect was correlated
with both an inhibition of ATPase activity and a PPI-
induced marked increase in drug retention within tumortd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ently of both tumor histology and the type of cytotoxic
drug [3].
More recently, it has been shown that the in vivo PPI-
mediated effect on human tumors is transient, particu-
larly in terms of pH gradient at the cellular level [4].
Lastly, PPI were able to increase sensitivity of cells
responding to standard chemotherapy, but also to revert
multidrug resistance (MDR) [3]. A PPI-based approach
might therefore be extremely interesting to test both in
solid tumors unresponsive to drugs and in tumors
responding to chemotherapy but undergoing MDR and
paying also the price of high level of toxicity of very
aggressive chemotherapy. Osteosarcoma is a rare tumor
with an overall incidence of 0.2 new cases/100,000. It is
more frequently diagnosed in adolescents and young
adults where it accounts for >10% of all solid cancers
[5]. Currenty, strategy is based on a combination of
surgery and chemotherapy. Chemotherapy is delivered
before and after surgical removal of the tumor (neoad-
juvant chemotherapy). The most effective drugs used
for osteosarcoma are methotrexate (MTX), cisplatin (CDP),
doxorubicin (ADM), and ifosfamide (IFO). In case of
patients without evident metastatic disease at presenta-
tion the event-free survival is 60% at 5 years [6]. Late
(>5 years) relapse are uncommon in patients with osteo-
sarcoma (6,7). Inadequate surgical control of the tumor
leads to local recurrence in about 5% of patients. In about
35% of patients tumor resistance towards the four-drug
combination therapy is responsible for the failure of the
systemic chemotherapy treatment [6]. The rationale for
neoadjuvant chemotherapy is based on an early use of
chemotherapy and on the possibility to assess chemo-
sensitivity by means of histological evaluation of the
chemotherapy-induced tumor necrosis on the surgical
specimen [7]. There is a strong correlation between
chemotherapy-induced tumor necrosis and prognosis in
patients with osteosarcoma [8] with a higher probability
of disease-free survival obtained in patients having a
good histologic tumor response to neoadjuvant chemo-
therapy [6,7]. Hence, the histologic response to neoadju-
vant chemotherapy is a very important predictive factor of
survival and a reliable parameter of chemosensitivity. Pre-
vious studies have shown that the preoperative chemo-
therapy dose-intensification [9] or the preoperative deliver
of intra-arterial cisplatin [10,11] are able to increase the
percentage of cases with a good response to neoadjuvant
chemotherapy. Both strategies are however associated
with more severe side effects and discomfort for the pa-
tient [9,11]. Preclinical data showing that pretreatment
of drug-resistant tumor cells with proton pump inhibitors
(PPI), renders tumor cells more sensitive to a variety of
anticancer drugs [3] have suggested that the administra-
tion of PPI as chemosensitizers might be an innovativeapproach to increase the sensitivity of osteosarcoma can-
cer cells to the currently used drugs. Moreover, an in vivo
study performed in companion animals with spontaneous
occurring tumors, including osteosarcoma, has shown an
amazing clinical response to high dosage PPI/chemotherapy
combination [12].
Based on the hypothesis that microenvironmental
acidity may represent a key factor in tumor homeostasis,
mostly involved in resistance to cytotoxic drugs, this
study presents preclinical and clinical data evaluating
the effectiveness of PPIs as chemosensitizer against
human osteosarcoma. More specifically, this study was
aimed at exploring the potential use of high dose PPI
pretreatment in osteosarcoma patients undergoing neoad-
juvant chemotherapy.
Materials and methods
In vitro studies
Cells
Continuous cell lines from human osteosarcoma (Saos-2,
MG-63), obtained from the American Type Culture Collec-
tion (ATCC, Rockville, MD), were maintained in Iscove's
Modified Dulbecco's Medium (IMDM, Invitrogen, Carlsbad,
CA), supplemented with 10% fetal bovine serum (FBS,
Mascia Brunelli, Milan, Italy), penicillin (100 U/ml) and
streptomycin (100 mg/ml) (Invitrogen) at 37°C and 5%
CO2. Only cells in exponential growth phase were used.
Cell proliferation assay
Cells were seeded in duplicate in 12-well plates
(3x104 cells/well for Saos-2 and 2x104 cells/well for
MG-63) in unbuffered medium. After 24 h the culture
medium was replaced with fresh medium containing
60 μM esomeprazole (ESOM) (Sigma-Aldrich) dissolved
in DMSO. As controls, cells were incubated with medium
at the same concentration of DMSO. After 24 h the
culture medium was replaced with fresh medium con-
taining 0.5-5-50 μM cisplatin (Sigma-Aldrich). After 72 h,
pH of the medium was tested and cells were harvested.
The number of viable cells was evaluated by the erythro-
sin B dye vital staining [13]. Results were expressed as
growth inhibition ratio in respect to cells in 0.5 μM cis-
platin medium without ESOM pretreatment. The ex-
periment was repeated three times in duplicate.
Statistical analysis
Statistical analysis was performed using the StatView™
5.0.1 software for Windows (SAS Institute, Cary, NC).
Differences were analysed using the non-parametric
Wilcoxon Signed Rank test (significant level of p < 0.05).
In vivo study
Female CB.17 SCID/SCID mice aged 4–5 weeks (Harlan,
Italy) were kept under specific pathogen-free conditions
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cages, and all food, water, and bedding were autoclaved
prior to use. Each mouse was injected subcutaneously in
the right flank with 3 x106 human osteosarcoma cells
(Saos-2) that had been resuspended in 0.2 mL of RPMI-
1640 containing 10% FCS. Once tumors became evident
(at least 0.10 cm, approximately 10 days after the tumor
cell injection), ESOM was administered by i.p. injection
[4] at a dose of 25 mg/kg. Cisplatin was administered
weekly by i.p. injection at a dose of 5 mg/kg. Tumor size
(mm3) was measured three times per week with calipers
with the formula length x width2. Morbidity was consid-
ered as the end-point according to standard clinical cri-
teria including oversized tumor (>1 cm), weight loss
(>20%), rough hair coat, and general illness. At least 5
mice were used for each treatment group. Data are
expressed as the mean value of tumor weight with 95%
confidence intervals. Mice were monitored for the dur-
ation of the in vivo experiments for body weight, hair
ruffling, and the presence of diarrhea. Animal care was
conformed to European Council Directive 86/609/EEC
and the study was approved by institutional review board.
Differences between groups were analyzed by Mann-
Whitney test, student T test or by ANOVA as appropriate.
Data are expressed as mean 6 SD and p values reported
are 2-sided.
Clinical study
The study was a multi-centre historically controlled trial,
evaluating the activity of a pre-treatment administration of
PPIs as chemosensitizers in a neoadjuvant chemotherapy
based on methotrexate (MTX), cisplatin (CDP), and adria-
mycin (ADM).
Patients aged ≤40 years with resectable nonmetastatic
osteosarcoma of the extremities, with normal bone marrow,
hepatic, cardiac and renal function, without contraindica-
tions to the use of MTX, CDP, ADM, were included into
the study and after given written informed consent. Patients
were instructed about the use of the study drug. In a separ-
ate sheet of the discharging letter they had to fill a table
reporting the exact time of administration of the study
drug and signs or symptoms related to the study drug.
Patients received, according to the standard strategy of
treatment for osteosarcoma [3] neoadjuvant chemother-
apy that in this study consisted of two blocks of MTX
(12 g/m2), CDP (120 mg/m2) and ADM (75 mg/m2)
(Figure 1). MTX (12 mg/m2, top dose 24 g) was given
i.v. over 4 hour (T0-T4) infusion. The minimum hydra-
tion required was 2.5 L/m2/day. From T24, folinc acid
rescue was started every 6 hours for 11 administration
(up to T84). CDP was given i.v. 120 mg/m2 over 48 hours.
The minimum hydration required was 2 L/m2/24 hours
After CDP infusion patients received ADM 75 mg/m2 i.v.
over 24 hours.All patients eligible for the study received the study
drug ESOM. This was orally administered in the two days
prior to each cytotoxic agent. Patients had to receive
ESOM the two days before chemotherapy because pre-
clinical studies have clearly shown that this is the only
effective approach is the pretreatment [3]. The daily
dose of ESOM was 60 mg/day (before MTX), that is
the minimal effective dose calculated on the basis of
the preclinical studies [3,4]. In patients weighting under
30 Kg the daily dose was reduced at 40 mg/day. Before
CDP/ADM cycles, the daily dose of ESOM was 120 mg/day.
The study drug was supplied by the local pharmacy.
Baseline studies included: complete blood count, serum
electrolytes, and glomerular filtration rate estimation;
serum alkaline phosphatase and lactate dehydrogenase levels;
bilirubin and aminotransferase levels and echocardiography.
After neoadjuvant chemotherapy, the patients under-
went surgical removal of the tumor.
Histological analysis of the tumor map was performed
in accordance with a method reported previously [8]. When
the percentage of tumor necrosis was equal or higher
than 90%, patients were classified as good responders
(GR); with a lower percentage they were defined as poor
responders (PR).
Diagnosis, histological subtype, and histological response
were reviewed by an expert panel of pathologists.
The rarity of osteosarcoma, with an incidence of 0.2/
100,000 new cases/year [5], made it difficult to run a
randomized phase 2 study, and for this reason it was
decided to perform a prospective phase 2 study with a
comparison with historical control.
The comparator of the present study was the previous
Italian Sarcoma Group ISG/OS-1 study, whose results
have already been published [14-17]. In particular, the
group of patients treated according to arm A, that had
received the same drugs and schedule adopted in the
present study, was used as comparator.
In ISG/OS-1 the percentage of patients with a good
pathologic response was 50%.
A sample size of 85 patients was calculated to detect a
difference of 15% or higher, between the study group
and the historical control (study power of 80%, type I
error of 5%).
Results
Preclinical studies
In vitro
This set of experiments was aimed at defining the ability
of the PPI ESOM to increase the sensitivity of human
osteosarcoma cells to cytotoxic drugs. We first investi-
gated the changes in the microenvironmental pH induced
by the osteosarcoma cells growth. Osteosarcoma cells
were able to acidify the medium by decreasing extracel-
lular pH. In fact, after 24 h of cell culture in unbuffered
Figure 1 In vitro studies on PPI effect on osteosarcoma cells. (a) Comparison of CDP activity with or without ESOM pre-treatment (60 μM) in
MG-63 cells. The activity of CDP is significantly higher in pretreated cells (significant level * for p < 0.05) for all CDP doses. (b) Comparison of CDP
activity with or without ESOM pre-treatment (60 μM) in Saos-2 cells The activity of ESOM is significantly higher in pretreated cells (significant level
* for p < 0.05) at 0.5 uM CDP dose.
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coma cell lines (MG-63 and Saos-2) was respectively
6.67 ± 0.01 and 6.89 ± 0.05. Thus, there was the suitable
condition for the best protonation of ESOM in order to
allow the transformation of the pro-drug to the active
molecule (tetracyclic sulfenamide).
Then we performed experiments aimed at evaluating
the PPI-induced sensitization of human osteosarcoma
cells to CDP. Results showed that 24 h ESOM pre-
treatment significantly increased the activity of CDP in
both osteosarcoma cell lines (Figure 1a and b). Particu-
larly, after ESOM pre-treatment, the activity of CDP, at
the lower dosage tested, was double in MG-63 and three
times in Saos-2 model (p = 0.0277) compared to control.
These results strongly supported the use of ESOM in
the therapy of osteosarcoma patients.In vivo
By analogy with the in vitro studies, we used the Saos-2
cellular model, ESOM as a PPI and CDP as one of the
drugs currently used in treatment of osteosarcoma patients.
The in vivo model was set up following the same procedure
of the studies performed for other tumor types [3]. Briefly,
CB.17 SCID/SCID mice were injected s.c. with 3 x106 hu-
man osteosarcoma cells (Saos-2) and after 10 days 25 mg/kg
ESOM was administered i.p., 24 hours before the i.p. injec-
tion of 5 mg/kg CDP. This treatment was repeated weekly
for up to 4 consecutive weeks. Tumor size was measured
three times/week until the end of the experiments. Three
groups of at least 5 mice were treated with CDP alone,
ESOM+CDP combination, or left untreated.
Results showed that, as expected, CDP alone induced
a significant inhibition of tumor growth, but also that
Table 1 Clinical characteristics of eligible patients
Variable No (%)
Gender Male 59 (60%)
Female 39 (40%)
Site Femur 49 (50%)
Tibia 33 (34%)
Humerus 8 (8%)
Other 8 (8%)
SAP High 26 (26%)
Normal 72 (74%)
LDH High 22 (22%)
Normal 76 (78%)
Histology Osteoblastic 65 (66%)
Chondroblastic 18 (18%)
Telangiectatic 10 (10%)
Fibroblastic 5 (5%)
Ferrari et al. Journal of Translational Medicine 2013, 11:268 Page 5 of 7
http://www.translational-medicine.com/content/11/1/268ESOM pre-treatment induced a complete inhibition of
tumor growth, with no evidence of the tumor at the end
of the experiments (Figure 2). Supporting previous re-
sults obtained with human cell lines of different histo-
types [3], ESOM alone, at this dosage and with this
schedule of treatment did not induce significant inhib-
ition of tumor growth (not shown). This set of experi-
ments further supported the potential use of PPI in
improving the effectiveness of chemotherapy in osteo-
sarcoma patients.
Clinical study
From January 2006 to December 2009, 99 patients [median
age 15 years (6–40)] were registered into the study. One of
them was excluded because a central revision did not con-
firm the diagnosis of osteoblastic osteosarcoma. All the 98
eligible patients were evaluable for histological response.
No protocol deviation was registered. The clinical charac-
teristics of eligible patients are summarized in Table 1.
A resection was performed in 93 patients, whereas 5 pa-
tients underwent amputation. The surgical margins evalu-
ation was available in 93 patients. In 9 patients the
surgical margins were classified as marginal (8 patients) or
wide but contaminated (3 patients), the remaining patients
had wide or radical surgical margins. On histology, a GR
was detected in 56 (57%) patients (Figure 3). According to
the histological histotype the highest rate of GR was seen
in patients with the chondroblastic histotype followed byFigure 2 In vivo effects of ESOM on tumor growth in CB.17
SCID/SCID mice. Mice were engrafted with Saos-2 cells via s.c.
injection in the right flank. At the time of tumor appearance
(approximately 7–10 days after injection), mice were left untreated or
were pre-treated with 25 mg/kg of ESOM 24 hrs before the i.p. injection
of CDP or treated with CDP alone. Tumor size was measured three times
per week, and volume was calculated as described in the “Methods”
section. The histograms represent mean +/− 95% confidence intervals of
tumor weight.those with telangiectatic, fibroblastic, and osteoblastic var-
iants (Figure 3). In the comparator group (ISG/OS-1), the
incidence of GR was 47%, close to that observed in the in-
vestigational group (Figure 3). According to the histotype,
a similar percentage of good response was observed in
osteoblastic and in the pool of fibroblastic and telangi-
ectatic osteosarcoma whereas in patients with chondro-
blastic osteosarcoma the incidence of GR was only 25%,
a remarkably lower rate as compared to the 61% re-
corded in the group of patients pre-treated with ESOM.
Overall, the incidence of leukopenia G4 was 28%,
thrombocytopenia G4 30%. The incidence of febrile neu-
tropenia was 27%. Red blood cells and platelets transfu-
sion were required in 18% and 16% of the chemotherapy
cycles respectively. The incidence of delayed MTX ex-
cretion was 3% with transient G1 renal toxicity in 3Figure 3 Incidence of GR in eligible patients (PPI-Osteosarcoma)
versus the comparator group (ISG/OS-1). Comparison among the
groups by means of Fisher’s exact test: Osteoblastic p = 0.32,
Fibroblastic + Telangectatic 0.70, Chondroblastic p = 0.07.
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lescents) experienced G4 transaminitis that in less than
30% of cases required medical treatment with steroids and
fluid i.v. administration. In no cases the liver toxicity was
cause of drug discontinuation, but it more frequently
caused delay in the subsequent course of chemotherapy.
No toxic deaths were reported. No serious adverse events
were reported related to the pretreatment with ESOM.
The toxicity profile reported in the ISG/OS-1 study
was similar to that observed in the PPI-Osteosarcoma
study [14].
Discussion
Microenvironmental acidity is a factor influencing the
tumor homeostasis. Preclinical data suggest that a low
pH is involved in resistance to cytotoxic drugs [3] and
that tumor alkalinization through proton pump inhibi-
tors (PPI), renders tumor cells more sensitive to chemo-
therapy [1,3].
Previous studies have shown as PPI have an anti-tumor
effect against different tumor types [4,18], supporting the
use of this family of compounds in the treatment of the
vast majority of human tumors. Moreover, since 2010 the
International Society for Proton Dynamics in Cancer
(ISPDC), has gathered a consistent part of scientists that
worldwide are studying tumor acidity and the proton dy-
namics underlying the low pH of tumors, with the aim to
explore new modalities of treatment for cancer [19].
The preclinical experiments have shown that PPI pre-
treatment induce a clear increase in the sensitivity of
human osteosarcoma cells to chemotherapeutics. The
in vitro experiments showed a significantly increase in
the CDP-mediated cytotoxicity following ESOM pre-
treatment against osteosarcoma cells. This set of experi-
ments also provided the proof of concept that osteosarcoma
cells cultured in unbuffered condition were fully able to
acidify the medium, just providing the suitable condition
for transformation of the ESOM pro-drug to the active
molecule. In fact, in this condition while CDP alone was
effective against MG-63 and Saos-2 osteosarcoma cells,
esomeprazole significantly increased the CDP-mediated
cytotoxicity at the lower dose of CDP. Notably, in MG-63
cells ESOM pre-treatment lowered ten times the dose of
CDP able to induce a 50% inhibition of cell growth
(0.5 μΜ vs 5 μΜ). The in vitro results were strongly
supported by the in vivo results obtained in the human
osteosarcoma-SCID mice xenografts. Consistently with
the results obtained with the human osteosarcoma cell
cultures, pre-treatment with ESOM significantly increased
the effectiveness of CDP alone on the growth of human
osteosarcoma in SCID mice, getting to a total inhibition of
the tumor growth at the end of the experiments.
Thus, we tested the effectiveness of PPI pre-treatment
in a clinical trial. The possibility to evaluate thepathological response to neoadjuvant chemotherapy by
mapping the resected specimen and the clear relation be-
tween chemo-induced tumor necrosis and survival makes
osteosarcoma an interesting model to assess a possible
role of PPIs as an innovative therapeutic solution. The rar-
ity of osteosarcoma made difficult to run a randomized
phase 2 study, and for this reason we decided to perform
a prospective phase 2 study with a comparison with his-
torical control. On the other hand the expected pathological
response to neoadjuvant chemotherapy in osteosarcoma is
well defined, based on several previous experiences [16,20].
Overall, the addition of PPIs, to MTX, CDP, and ADM
allowed a higher rate of GR compared to the control group,
although this did not reach the statistical significance. It is
important to notice that by comparing the histological re-
sponse according to the different histotypes arises a differ-
ence for the chondroblastic variant, with a 61% of good
responses in PPI pretreated patients (25% was the good re-
sponse rate in the control group). It is well known that the
expected rate of GR is low in the chondroblastic variant of
osteosarcoma [20,21] and the results achieved in the
present study suggest a relation between chondroblastic
component, tumor acidity and the use of PPIs.
On the other hand it is important to underline that
the results reported were achieved with a multidrug regi-
men, and that the drugs used have different pharmaco-
kinetics and pharmacodynamics characteristic. For this
reason the study does not allow any conclusions on the
possible interaction between PPIs and each single drug
used in the protocol.
The chemotherapy protocols currently used are charac-
terized by a remarkable toxicity. Previous studies per-
formed in the clinical centers involved in this project have
shown that IV grade neutropenia is detectable in > 40% of
patients despite the prophylactic treatment with G-CSF.
The toxicity profile registered in patients who received pre-
treatment with ESOM was the same observed in patients
having the same clinical characteristics and who received
the same chemotherapy protocol. Preclinical data showing
that PPI pre-treatment increases the sensitivity of human
osteosarcoma cells to antineoplastic agents (particularly to
CDP) is an interesting basis for further studies combining
PPIs and antineoplastic agents at a reduced dose in an at-
tempt to ameliorate the chemotherapy-related toxicity.
It is note worth, that a recent report highlighted the
interaction between PPIs and MTX toxicity [22] leading
to an increased MTX due to a concomitant use of the
two drugs. In our report, however, the toxicity profile of
MTX was not modified by pre-treatment with ESOM.
Conclusions
This is the first translational study reporting preclinical
and clinical investigations on the use of PPI in human
osteosarcoma. Pre-clinical data clearly show that PPIs
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cells to chemotherapeutic drugs, such as CDP, and suggest
that CDP could be delivered at reduced dose in an attempt
to achieve a better toxicity profile.
Clinical data, while obtained with a surrogate endpoint,
such as the chemotherapy-induced tumor necrosis, repre-
sent the first proof of concept that PPI may be included
in the future strategies against cancer, and in particular
in the treatment of osteosarcoma patients. The high
pathological response rate in patients with the chondroblas-
tic variant of osteosarcoma recommends further studies to
assess the relation between PPIs and sarcoma tumors with
chondroblastic component.
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